CHRONIC KIDNEY DISEASE AND ITS MANAGEMENT:  A REVIEW by Mehvish Adil *and Mariam Zaka
IAJPS 2017, 4 (11), 3803-3805            Mehvish Adil and Mariam Zaka          ISSN 2349-7750 
 
 w w w . i a j p s . c o m  
 
Page 3803 
 
                                          CODEN [USA]: IAJPBB                          ISSN: 2349-7750 
 
 INDO AMERICAN JOURNAL OF 
PHARMACEUTICAL SCIENCES 
 
     
 
 
Available online at: http://www.iajps.com                                   Review Article 
 
CHRONIC KIDNEY DISEASE AND ITS MANAGEMENT:  
A REVIEW 
Mehvish Adil *and Mariam Zaka 
Lahore College for Women University, Jail Road Lahore, Pakistan 
Abstract: 
Chronic kidney disease (CKD) is a major public health problem worldwide and its prevalence is increasing day by 
day. CKD defines as kidney damage or a decreased glomerular filtration rate of less than 60 mL/min/1.73 m2 for 3 
or more months irrespective of cause. It has deeper effects on morbidity, mortality, health care costs, as well as on 
patient quality of life and on important social implications. CKD patients have several other co-morbidities such as 
hypertension, diabetes mellitus, coronary artery disease and anemia , and due to these co morbidities,  patients are 
on multiple medications, and are higher risk of developing drug-related problems. Hypertension is a major 
promoter of the decline in glomerular filtration rate (GFR) and a strong independent risk factor along with 
Diabetes mellitus for CKD. Treatment of high blood pressure is recommended for all individuals with, or at risk of, 
chronic kidney disease. Glycemic control can help to prevent the onset of early stages of chronic kidney disease in 
individuals with diabetes. Better management of CKD can slow the progression of CKD, prevent complications, and 
reduce cardiovascular-related outcomes and improve patient’s quality of life. 
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INTRODUCTION: 
Chronic kidney disease (CKD) is a worldwide public 
health problem. Chronic kidney disease is a global 
threat to health for developing and under developing 
countries because of an increasing incidence, poor 
outcome, and high cost of treatment. It is a general 
term for heterogeneous disorders affecting kidney 
structure and function. The Kidney Disease 
Outcomes Quality Initiative (K/DOQI) of the 
National Kidney Foundation (NKF) defines CKD as 
“ kidney damage or a decreased glomerular filtration 
rate of less than 60 mL/min/1.73 m2 for 3 or more 
months, irrespective of the cause”. [1] 
Chronic kidney disease is a common disorder and its 
prevalence is increasing worldwide day by day.[2] 
According to the World Health Report 2002 and 
Global Burden of Disease (GBD) project, diseases of 
the kidney and urinary tract contribute to the global 
burden of diseases, with approximately 850,000 
deaths every year and 15,010,167 disability-adjusted 
life years . They are the 12th cause of death and the 
17th cause of disability, in the world. [3] 
Chronic kidney disease has profound effects on 
morbidity, mortality, and health care costs, as well as 
on important social implications. Pakistan reveals an 
alarmingly high burden. Approximately 15 to 20 
percent of persons 40 years of age or older have a 
reduced estimated GFR. Evidence indicates that 
chronic kidney disease develops is about a third of 
patients with diabetes. The burden of hypertension is 
even higher — affecting about one third of 45 years 
of age or older. Although the average Pakistani adult 
visits a primary care physician four to five times each 
year, 64 percent of adults have never had their blood 
pressure measured, and 70 percent of patients with 
hypertension and 50 percent of patients with diabetes 
are unaware of their condition. Compounding the 
problem of under detection are gaps in the knowledge 
of some Pakistani physicians about the management 
of hypertension and diabetes, which lead to under 
treatment and a lack of preventive measures against 
chronic kidney disease. Against this backdrop of poor 
medical practices, patients with kidney failure are 
faced with the high cost of renal-replacement 
therapy.[4] 
Disease and management are classified according to 
stages of disease severity, which are assessed from 
glomerular filtration rate (GFR) and albuminuria, and 
clinical diagnosis (cause and pathology). Chronic 
kidney disease can be detected with routine 
laboratory tests, and some treatments can prevent 
development and slow disease progression, reduce 
complications of decreased GFR and risk of 
cardiovascular disease, and improve survival and 
quality of life.[5] 
The major part of this increase is caused by such 
lifestyle-related factors as hypertension and diabetic 
nephropathy. The association between obesity, 
smoking, and physical activity and chronic kidney 
disease (CKD)  are important. It is known that 
obesity leads to ESRD through diabetes mellitus and 
hypertension, but obesity also can contribute directly 
to kidney damage through obesity-related 
glomerulopathy, mechanical compression, and a 
cascade of other hemodynamic and metabolic 
mechanisms. [6] 
It is recommended  that both diabetic and non-
diabetic adults with CKD and urine albumin 
excretion <30 mg/24 hours (or equivalent) whose  BP 
is consistently >140 mm Hg systolic or >90 mm Hg 
diastolic should be treated with BP-lowering drugs to 
maintain a BP that is consistently ≤140 mm Hg 
systolic and ≤90 mm Hg diastolic and also 
recommended that an ARB [angiotensin-receptor 
blocker] or ACE-I [angiotensin-converting enzyme 
inhibitor] be used in both diabetic and non-diabetic 
adults with CKD and urine albumin excretion >300 
mg/24 hours . 
Control of blood pressure and reduction of 
proteinuria are critical in preventing CKD 
progression. The reduction of proteinuria using 
renin–angiotensin–aldosterone system (RAAS) 
interruption slows progression of both diabetic and 
nondiabetic nephropathy. Lowering blood pressure 
also slows CKD progression, breaking a potentially 
vicious cycle associating hypertension and CKD. 
Evidence is insufficient to recommend combining an 
angiotensin-converting enzyme inhibitor with 
angiotensin-receptor blockers to prevent CKD 
progression.  Although JNC 8 recommends a RAAS 
blocker for all patients with chronic kidney disease, 
Some chronic kidney disease patients can develop 
hyperkalemia or a decreased estimated glomerular 
filtration rate after starting an ACE-I or an ARB. 
Monitoring should include assessment of serum 
potassium and estimated glomerular filtration rate 
approximately within several weeks after initiation or 
dose escalation. When hyperkalemia develops, 
outpatient management strategies include 
identification and restriction of dietary potassium, 
treatment of metabolic acidosis if appropriate, 
consideration of thiazide or loop diuretic use to 
increase potassium excretion, and treatment with a 
potassium-binding exchange resin. Discontinuation 
of the RAAS blocker should be considered only if 
these interventions fail.[7] 
Vitamin D deficiency may also be associated with the 
progression of renal function in CKD. Vitamin D and 
derivatives have been widely used in the management 
of CKD, for example, the control of 
hyperparathyroidism. The different Vitamin D 
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analogs have differential effects on physiological 
function, which could be classified by the activity. 
Nutritional Vitamin D25 can be supplemented by oral 
intake of vitamin D rich or fortified diets is non 
biological active form such as ergo calciferol, 
cholecalciferol and traditionally the active forms, 
1,25(OH)2D, known as hormone are calcitriol and 
alfacalcidol. More recently, four Vitamin D analogs 
have been introduced in the nephrology area and play 
an increasingly important role in CKD treatment 
which is doxercalciferol, paricalcitol, oxacalcitriol 
and falecalcitriol. [8] 
Better management of CKD can slow the progression 
of CKD, prevent complications, and reduce 
cardiovascular-related outcomes. Early referral to a 
nephrologist has been shown to improve outcomes 
for those who progress to end-stage renal disease. [9] 
Aerobic exercise in hemodialysis patients has been 
reported to enhance insulin sensitivity, improve lipid 
profile, increase hemoglobin, increase strength, 
decrease blood pressure, and improve quality of life. 
[10] 
 
CONCULSION: 
This study revealed that that most commonly 
observed stage of chronic kidney disease was end 
stage renal disease. Calcium channel blockers and 
insulin was most commonly prescribed drugs for 
hypertensive and diabetic patients with chronic 
kidney disease. CKD leads to complications such as 
anemia, bone disorders & hyperphosphatemia, to 
manage these complications vitamin D supplements, 
erythropoietin therapy & phosphate binders were 
most commonly prescribed.  
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